These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 25876971)
1. [Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts]. Lou J; Gao Z; Jiang Z; Chen J; Chen R; Zhang X Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Jan; 33(1):33-6. PubMed ID: 25876971 [TBL] [Abstract][Full Text] [Related]
2. Improving the Accuracy of Mesothelioma Diagnosis in China. Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630 [TBL] [Abstract][Full Text] [Related]
3. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma. Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012 [TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
5. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. Tandon RT; Jimenez-Cortez Y; Taub R; Borczuk AC Arch Pathol Lab Med; 2018 Feb; 142(2):236-242. PubMed ID: 29048219 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
8. [Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases]. Lao I; Chen Q; Yu L; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):364-9. PubMed ID: 25208984 [TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2008 Feb; 58(2):75-83. PubMed ID: 18199156 [TBL] [Abstract][Full Text] [Related]
10. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations. Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895 [TBL] [Abstract][Full Text] [Related]
11. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750 [TBL] [Abstract][Full Text] [Related]
12. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application]. Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072 [No Abstract] [Full Text] [Related]
13. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557 [TBL] [Abstract][Full Text] [Related]
15. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid]. Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357 [No Abstract] [Full Text] [Related]
16. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236 [TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Ordóñez NG Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136 [TBL] [Abstract][Full Text] [Related]
20. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma. Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]